GlassScriptPhysician profile
Ryan R Sefcik
NPI 1336448331
$7,286.42
in general payments reported to CMS, 2019-2025
29 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $398 · 2021: $887 · 2022: $1,207 · 2023: $1,251 · 2024: $1,697 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.50 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,983.67 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $800.45 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $493.96 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $485.22 | 2022-2025 | Vemlidy, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.41 | 2019-2025 | Xifaxan |
| Celgene Corporation | $307.27 | 2021-2023 | Zeposia |
| Pfizer INC. | $263.75 | 2019-2025 | |
| Genzyme Corporation | $218.10 | 2023-2024 | |
| Madrigal Pharmaceuticals | $188.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $161.51 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $104.53 | 2019 | |
| Nestle Healthcare Nutrition INC. | $104.20 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $101.00 | 2024-2025 | Vowst |
| Mauna Kea Technologies, INC. | $96.07 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $94.38 | 2021-2024 | Linzess |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $73.56 | 2019 | |
| Ferring Pharmaceuticals INC. | $57.55 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $50.62 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $47.64 | 2022-2024 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $41.38 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $38.44 | 2020-2022 | |
| Ardelyx, INC. | $32.61 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $25.05 | 2024 | Sucraid |
| Olympus America INC. | $24.09 | 2022 | |
| Organon LLC | $21.46 | 2024 | |
| Ucb, INC. | $18.30 | 2019 | |
| Shionogi INC | $17.18 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.47 | 2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sefcik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.